Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2023 Filed Jan 18, 2023 21:28 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $224.36 | $1,273,268.54 |
DisclosureSEC source: 0001127602-23-001650 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $220.59 - $225.635. The price reported above reflects the weighted average sale price. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 21:28 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-001650 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:54 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,500 | $210.07 | $315,105.00 |
DisclosureSEC source: 0001127602-23-000789 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,172 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 19:53 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-027648 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,890 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 19:53 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $215.63 | $1,223,727.49 |
DisclosureSEC source: 0001127602-22-027648 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $214.14 - $220.37. The price reported above reflects the weighted average sale price. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 19:53 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-027648 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 20:07 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,500 | $229.81 | $344,715.00 |
DisclosureSEC source: 0001127602-22-026963 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,672 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 18:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GiftResMed Common Stock | 7,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026463 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,172 F1 · kind: Gift of shares to The San Diego Foundation, a 501(c)(3) nonprofit organization. Mr. Pendarvis has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 18:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 683 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-22-026463 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,540 Underlying: ResMed Common Stock · 683 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 18:58 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 683 | $146.34 | $99,950.22 |
DisclosureSEC source: 0001127602-22-026463 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:32 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 33,239 | $224.40 | $7,458,831.60 |
DisclosureSEC source: 0001127602-22-026363 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:32 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 56,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026363 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,139 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on November 23, 2022, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:24 UTC |
Douglas Robert AndrewPresident and COO
|
Tax withholdingResMed Common Stock | 19,425 | $224.40 | $4,358,970.00 |
DisclosureSEC source: 0001127602-22-026361 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,556 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:24 UTC |
Douglas Robert AndrewPresident and COO
|
GrantResMed Common Stock | 32,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026361 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,981 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on November 23, 2022, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:13 UTC |
Ghoshal KaushikPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 4,318 | $224.40 | $968,959.20 |
DisclosureSEC source: 0001127602-22-026358 · form4.xml · nonDerivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,704 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:13 UTC |
Ghoshal KaushikPresident, SaaS Business
|
GrantResMed Common Stock | 7,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026358 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,022 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on November 23, 2022, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 22:56 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 14,577 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026356 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,880 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on November 23, 2022, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 22:37 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 6,911 | $224.40 | $1,550,828.40 |
DisclosureSEC source: 0001127602-22-026352 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,789 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 22:37 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 12,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026352 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,700 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on November 23, 2022, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 21:42 UTC |
Leong JustinPresident, Asia Latin America
|
GrantReMed Common Stock | 6,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026349 · form4.xml · nonDerivative · entry 3 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,741 F2 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on November 23, 2022, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:42 UTC |
Leong JustinPresident, Asia Latin America
|
Exercise / conversionResMed Common Stock Options · Derivative | 15,000 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-026349 · form4.xml · derivative · entry 4 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 15,000 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:42 UTC |
Leong JustinPresident, Asia Latin America
|
SaleReMed Common Stock | 3,777 | $229.50 | $866,819.61 |
DisclosureSEC source: 0001127602-22-026349 · form4.xml · nonDerivative · entry 2 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,817 F1 · price: This transaction was executed in multiple trades at prices ranging from $229.42 $229.56. The price reported above reflects the weighted average sale price. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:42 UTC |
Leong JustinPresident, Asia Latin America
|
Exercise / conversionReMed Common Stock | 15,000 | $57.76 | $866,400.00 |
DisclosureSEC source: 0001127602-22-026349 · form4.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:24 UTC |
BLAISE LUCILEPresident, Sleep & RC Business
|
Tax withholdingResMed Common Stock | 75 | $224.40 | $16,830.00 |
DisclosureSEC source: 0001127602-22-026264 · form4.xml · nonDerivative · entry 3 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,552 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/18/2021. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:24 UTC |
BLAISE LUCILEPresident, Sleep & RC Business
|
Tax withholdingResMed Common Stock | 78 | $224.40 | $17,503.20 |
DisclosureSEC source: 0001127602-22-026264 · form4.xml · nonDerivative · entry 2 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,627 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:24 UTC |
BLAISE LUCILEPresident, Sleep & RC Business
|
Tax withholdingResMed Common Stock | 114 | $224.40 | $25,581.60 |
DisclosureSEC source: 0001127602-22-026264 · form4.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,705 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 01:38 UTC |
Leong JustinPresident, Asia Latin America
|
GrantResMed Common Stock Options · Derivative | 9,973 | $224.58 Strike: $224.58 | $2,239,736.34 |
DisclosureSEC source: 0001127602-22-026103 · form4.xml · derivative · entry 2 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,973 Underlying: ResMed Common Stock · 9,973 shares Expires 2029-11-16 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2023, 2024 and 2025. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 01:14 UTC |
Ghoshal KaushikPresident, SaaS Business
|
GrantResMed Common Stock Options · Derivative | 7,314 | $224.58 Strike: $224.58 | $1,642,578.12 |
DisclosureSEC source: 0001127602-22-026101 · form4.xml · derivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,314 Underlying: ResMed Common Stock · 7,314 shares Expires 2029-11-16 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2023, 2024 and 2025. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 01:08 UTC |
Douglas Robert AndrewPresident and COO
|
GrantResMed Common Stock Options · Derivative | 31,649 | $224.58 Strike: $224.58 | $7,107,732.42 |
DisclosureSEC source: 0001127602-22-026099 · form4.xml · derivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,649 Underlying: ResMed Common Stock · 31,649 shares Expires 2029-11-16 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2023, 2024 and 2025. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 00:55 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock Options · Derivative | 36,569 | $224.58 Strike: $224.58 | $8,212,666.02 |
DisclosureSEC source: 0001127602-22-026096 · form4.xml · derivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,569 Underlying: ResMed Common Stock · 36,569 shares Expires 2029-11-16 F1 · kind: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2023, 2024 and 2025. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 00:18 UTC Amendment |
BLAISE LUCILEPresident, Sleep & RC Business
|
GrantResMed Common Stock Options · Derivative | 2,410 | $224.58 Strike: $224.58 | $541,237.80 |
DisclosureSEC source: 0001127602-22-026089 · form4a.xml · derivative · entry 2 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,410 Underlying: ResMed Common Stock · 2,410 shares Expires 2029-11-16 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2023, 2024 and 2025. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:43 UTC |
Tan DesneyDirector
|
GrantResMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026087 · form4.xml · nonDerivative · entry 1 Tan Desney · CIK 0001890548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,078 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:38 UTC |
Hernandez JohnDirector
|
GrantResMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026085 · form4.xml · nonDerivative · entry 1 Hernandez John · CIK 0001890555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,078 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:11 UTC |
TAYLOR RONALD RDirector
|
GrantResMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026078 · form4.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,847 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:06 UTC |
SULPIZIO RICHARDDirector
|
GrantResMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026076 · form4.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,945 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 22:59 UTC |
Gill HarjitDirector
|
GrantResMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026072 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,266 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 22:54 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026069 · form4.xml · nonDerivative · entry 1 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,581 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 22:18 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026046 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,496 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 22:11 UTC |
Burt CarolDirector
|
GrantResMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026043 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,078 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2022 Filed Nov 21, 2022 21:33 UTC |
De Witte JanDirector
|
GrantReMed Common Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026159 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,111 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:52 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-025860 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,565 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:52 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $224.64 | $1,274,837.11 |
DisclosureSEC source: 0001127602-22-025860 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,024 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.13 $226.34. The price reported above reflects the weighted average sale price. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:52 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-025860 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 23:20 UTC |
BLAISE LUCILEPresident, Sleep & RC Business
|
SaleResMed Common Stock | 169 | $225.18 | $38,055.42 |
DisclosureSEC source: 0001127602-22-025844 · form4.xml · nonDerivative · entry 2 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,335 F2 · balance_after: Includes 72.515 shares of ResMed stock purchased on October 31, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 23:20 UTC |
BLAISE LUCILEPresident, Sleep & RC Business
|
Exercise / conversionResMed Common Stock | 516 | $225.18 | $116,192.88 |
DisclosureSEC source: 0001127602-22-025844 · form4.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 22:40 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 16,888 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-22-025832 · form4.xml · derivative · entry 6 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 16,888 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 22:40 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 1,144 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-22-025832 · form4.xml · derivative · entry 5 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,888 Underlying: ResMed Common Stock · 1,144 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 22:40 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 11,280 | $222.07 | $2,504,939.45 |
DisclosureSEC source: 0001127602-22-025832 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,186 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $221.77 $223.56. The price reported above reflects the weighted average sale price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 22:40 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 16,888 | $58.24 | $983,557.12 |
DisclosureSEC source: 0001127602-22-025832 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 22:40 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 1,144 | $58.24 | $66,626.56 |
DisclosureSEC source: 0001127602-22-025832 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.